Date: 2013-09-19
Type of information: R&D agreement
Compound: TIQUAS (Targeted In-depth QUAntification of cell Signalling) phosphoproteomics platform
Company: Activiomics (UK) Kyowa Hakko Kirin (Japan)
Therapeutic area: Technology - Services
Type agreement: R&D
collaboration
Action mechanism: TIQUAS makes use of sophisticated mass spectroscopy-based techniques to detect and quantify thousands of phosphorylation sites from a cell/tissue extract. This provides clues as to which proteins or pathways are activated, since change in phosphorylation status is indicative of a change in protein activity.
Disease:
Details: * On September 19, 2013, Activiomics has announced it has extended its Contract Research Agreement with Japanese pharmaceutical company Kyowa Hakko Kirin (KHK) by entering into a new research programme. Activiomics will apply its novel TIQUAS (Targeted In-depth QUAntification of cell Signalling) phosphoproteomics platform to elucidate signalling mechanisms generated by lead compounds supplied by KHK in relevant cell-based systems.
This collaboration falls within Activiomics’ strategic partnership with BioFocus. In June 2012, BioFocus and Activiomics have announced a strategic alliance which will allow BioFocus to offer its customers Activiomics’ proteomics services to improve identification of novel targets for drug discovery and biomarkers for diagnostics. Activiomics’ proprietary technology, TIQUAS provides valuable insights into which proteins or pathways have been activated following a cell signaling event. It can be used to identify and validate prognostic and predictive biomarkers as well as to provide high-value drug mode of action information for the pharmaceutical and biotechnology industry.
Financial terms:
Latest news:
